Anew combined analysis of three clinical trials has revealed that an artificial pancreas developed at the University of Virginia Center for Diabetes Technology improves blood sugar control for people aged between two and 72 with type 1 diabetes.
The artificial pancreas is manufactured by Tandem Diabetes Care and marketed as the Control-IQ system.
The study found an average of 2.8 additional hours a day of controlled blood sugar within the target range in participants using the artificial pancreas across the three trials, compared with participants in control groups who received standard treatment to manage their blood sugar.
